Breye Therapeutics has a paper on its oral danegaptide treatment for patients with NPDR published in Science Translational Medicine
Breye Therapeutics announces that it has had a paper on its lead asset danegaptide published in the prestigious journal Science Translational Medicine
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- The AI Triad Releases Business Before AI, a Guide to Turning AI Productivity Into Business Results
- Rent Wardrobe in Delhi Instead of Buying in 2026 as ₹15,000 Purchase Costs and a Three-Month Minimum Tenure Push Households Toward ₹256 Per Month Cupboard and Almirah Rental Plans From Rentomojo
- Durable Roofing Launches Industrial Roof Project Planning Resource
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →